Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia
Authors:
- Anne BurdessABAnne Burdess
- Alastair F. NimmoANAlastair F. Nimmo
- O. James GardenOGO. James Garden
- John A. MurieJMJohn A. Murie
- A. Raymond W. DawsonADA. Raymond W. Dawson
- Keith A. A. FoxKFKeith A. A. Fox
- David E. NewbyDNDavid E. Newby
- 1 July 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 252 (1) , 37-42
Abstract
Patients with critical limb ischemia have a perioperative cardiovascular morbidity comparable to patients with acute coronary syndromes. We hypothesized that perioperative dual antiplatelet therapy would improve biomarkers of atherothrombosis without causing unacceptable bleeding in patients undergoing surgery for critical limb ischemia. In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58). Platelet activation and myocardial injury were assessed by flow cytometry and plasma troponin concentrations, respectively. Clopidogrel reduced platelet-monocyte aggregation before surgery (38%-30%; P = 0.007). This was sustained in the postoperative period (P = 0.0019). There were 18 troponin-positive events (8 [16.0%] clopidogrel vs. 10 [17.2%] placebo; relative risk [RR]: 0.93, 95% confidence interval [CI]: 0.39-2.17; P = 0.86). Half of troponin-positive events occurred preoperatively with clopidogrel causing a greater decline in troponin concentrations (P < 0.001). There was no increase in major life-threatening bleeding (7 [14%] vs. 6 [10%]; RR: 1.4, 95% CI: 0.49-3.76; P = 0.56) or minor bleeding (17 [34%] vs. 12 [21%]; RR 1.64, 95% CI: 0.87-3.1; P = 0.12), although blood transfusions were increased (28% vs. 12.6%, RR: 2.3, 95% CI: 1.0-5.29; P = 0.037). In patients with critical limb ischemia, perioperative dual antiplatelet therapy reduces biomarkers of atherothrombosis without causing unacceptable bleeding. Large-scale randomized controlled trials are needed to establish whether dual antiplatelet therapy improves clinical outcome in high-risk patients undergoing vascular surgery.Keywords
This publication has 40 references indexed in Scilit:
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2006
- Peri-operative Myocardial Injury in Patients Undergoing Surgery for Critical Limb IschaemiaEuropean Journal of Vascular and Endovascular Surgery, 2005
- Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary SyndromeCirculation, 2004
- Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgeryJACC, 2003
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- Cardiac Troponin I Predicts Short-Term Mortality in Vascular Surgery PatientsCirculation, 2002
- Platelet–Monocyte AggregatesCirculation, 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Mortality over a Period of 10 Years in Patients with Peripheral Arterial DiseaseNew England Journal of Medicine, 1992
- Perioperative myocardial ischemia in patients undergoing noncardiac surgery—I: Incidence and severity during the 4 Day perioperative periodJACC, 1991